- Home
- AIO vs FTH Comparison
AIO vs FTH Comparison
Compare AIO & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$28.80
Company Overview
Basic Information| Metric | AIO | FTH |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.8M | 860.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIO | FTH |
|---|---|---|
| Price | $26.67 | $28.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.8K | ★ 298.4K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.91 | $17.50 |
| 52 Week High | $28.60 | $37.90 |
Technical Indicators
Market Signals| Indicator | AIO | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 55.28 |
| Support Level | $25.05 | $22.69 |
| Resistance Level | $26.67 | $31.61 |
| Average True Range (ATR) | 0.51 | 2.99 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 93.17 | 66.92 |
Price Performance
Historical Comparison AIO
FTH
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.